Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1997 May-Jun;15(3):303-6.

Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study

Affiliations
  • PMID: 9177927
Clinical Trial

Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study

G Nesher et al. Clin Exp Rheumatol. 1997 May-Jun.

Abstract

Objective: To define the optimal corticosteroid dose regimen in the initial treatment of temporal arteritis (TA).

Methods: We conducted a retrospective long-term evaluation of the efficacy and toxicity of corticosteroid treatment in 77 TA patients treated with three different dose-regimens: group A starting at 30-40 mg/d of prednisone, group B > 40-60 mg/d, and group C > 60 mg/d.

Results: The 3 patient groups were similar with regard to the mean age, male/female ratio, mean duration of follow-up, percentage of positive temporal artery biopsies, and rate of steroid tapering. There was a positive correlation between the starting dose and the cumulative dose of steroids at one year. Treatment efficacy was similar among the groups: cumulative cure rates (i.e. patients off steroids without exacerbation of TA for 6 months or more) were 11-13%, 29-35%, and 48-50% after 1, 2, and 3 years, respectively. In addition, the rates of disease flare were similar among the groups after 3 years of follow up, although group C patients tended to have fewer TA exacerbations during the first year compared to the other groups. In contrast, group A patients developed significantly fewer steroid side effects: 36% compared to 78% and 88% in groups B and C.

Conclusion: The group A steroid regimen, starting with 30-40 mg/d and tapering to 10 mg/d within 6 months and to 5-7.5 mg/d within 1 year, was effective and less toxic in this patient population, than the two higher dose regimens.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources